Literature DB >> 15158071

Herpes simplex virus genotyping: multiple optional PCR-based RFLP systems and a non-isotopic single-strand conformation polymorphism method.

Martín C Abba1, Carlos D Golijow.   

Abstract

Polymerase chain reaction (PCR)-based methods for herpes simplex virus (HSV) types I/II genotyping are described. These methods are based on the single-stranded conformation properties of DNA molecules obtained by PCR (PCR-SSCP) and restriction fragment analysis of PCR products (PCR-RFLP). With the aim to analyse these two genotyping techniques, genomic DNA from the standard viral strains KOS and G, and also 79 normal cervical samples were studied for HSV I/II. Sequence analysis showed 19 different RFLP possible systems for HSV typing. Five systems were used in this study and all led to the expected fragments obtained by sequence analysis. PCR-SSCP showed distinct patterns for both viral types and had 100% of concordance with PCR-RFLP results. The prevalence of herpes simplex virus in the normal cervical samples were 21.5% (17 out of 79), the most frequent viral type was HSV-2, with a prevalence of 71% (12 out of 17). Both techniques appeared suitable for HSV I/II genotyping and are easy to perform in most clinical laboratories.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158071     DOI: 10.1016/j.jviromet.2004.01.013

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  2 in total

1.  Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism.

Authors:  Sonia Burrel; Zaïna Ait-Arkoub; Delphine Voujon; Claire Deback; Emiliana P Abrao; Henri Agut; David Boutolleau
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

2.  Rapid diagnosis of herpetic encephalitis in children by PCR-microarray technology for simultaneous detection of seven human herpes viruses.

Authors:  Jianrong Shi; Yidong Wu; Meiting Cai; Shiqiang Shang
Journal:  Eur J Pediatr       Date:  2009-08-16       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.